Latest revenue
$392.9M
as of 2026-03-31
Latest net income
$-66.5M
as of 2026-03-31
Net margin
-16.9%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think ALKS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $7.13B
- Enterprise value
- $8.29B
- P/E (trailing)
- 29.5×
- Forward P/E
- —
- P/B
- 4.07×
- Dividend yield
- 0.0%
- 52-wk high
- $44.57
- 52-wk low
- $25.17
- Beta
- —
- Shares out
- 166.7M
5-year trend
What this company does
Item 1. Business The following discussion contains forward-looking statements. Actual results may differ significantly from those expressed or implied in the forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements” on page 3 of this Annual Report. Factors that might cause future results to differ materially from those expressed or implied in the forward-looking statements include, but are not limited to, those discussed in “Item 1A—Risk Factors” and elsewhere in this Annual Report. Overview Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial…
AI summary unavailable — showing raw filing excerpt
Generated from ALKS's filing dated 2026-02-25
Key risks
Item 1A. Risk Factors You should consider carefully the risks described below in addition to the financial and other information contained in this Annual Report, including our financial statements and related notes thereto and the matters addressed under the caption “Cautionary Note Concerning Forward-Looking Statements,” and in our other public filings with the SEC. If any events described by the following risks actually occur, such events could materially adversely affect our business, financial condition, cash flows or results of operations. This could cause the market price of our ordinary shares to materially decline. The risks described below are not intended to be exhaustive and are…
AI summary unavailable — showing raw filing excerpt
Generated from ALKS's filing dated 2026-02-25
Profitability
Operating margin
17.2%
36.3%Net margin
16.4%
30.5%Return on equity
16.5%
46.0%Return on assets
9.7%
45.6%Leverage
Debt / equity
0.70×
1.6%Long-term debt / equity
0.28×
5.7%Debt / assets
41.1%
1.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $392.9M | +28.2% | $-66.5M | -395.9% | -16.9% |
Q4 2025 2025-12-31 | $384.5M | -10.6% | $49.3M | -66.3% | 12.8% |
Q3 2025 2025-09-30 | $394.2M | +4.2% | $82.8M | -10.4% | 21.0% |
Q2 2025 2025-06-30 | $390.7M | -2.1% | $87.1M | -4.7% | 22.3% |
Q1 2025 2025-03-31 | $306.5M | -12.5% | $22.5M | -39.0% | 7.3% |
Q4 2024 2024-12-31 | $430.0M | — | $146.5M | — | 34.1% |
Q3 2024 2024-09-30 | $378.1M | -0.7% | $92.4M | +93.4% | 24.4% |
Q2 2024 2024-06-30 | $399.1M | -35.4% | $91.4M | -53.2% | 22.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ALKS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$5.2M
Net activity
−$5.2M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2026-05-04 | David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $33.20 | $67.5K | |
| 2026-05-01 | Craig C. Hopkinson EVP R&D, Chief Medical Officer | Sale | 9,000 | $33.40 | $300.6K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALKS
Institutional value
$2.71B
Total shares held
78.7M
Distinct holders
221
-142 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 28.3M | $1.00B | +42.0K (+0.1%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 9.5M | $336.3M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 7.4M | $262.6M | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 4.5M | $159.9M | +109.6K (+2.5%) | Added |
| 5 | JPMORGAN CHASE & CO | 4.1M | $123.7M | -1.1M (-20.9%) | Trimmed |
| 6 | FIRST TRUST ADVISORS LP | 3.0M | $105.0M | +1.5M (+104.2%) | Added |
| 7 | PRIMECAP MANAGEMENT CO/CA/ | 2.5M | $89.8M | -24.3K (-0.9%) | Trimmed |
| 8 | Nuveen, LLC | 2.5M | $87.0M | +33.5K (+1.4%) | Added |
| 9 | VANGUARD FIDUCIARY TRUST CO | 1.1M | $39.9M | — | New |
| 10 | Artisan Partners Limited Partnership | 1.1M | $39.3M | -237.4K (-17.6%) | Trimmed |
| 11 | Bank of New York Mellon Corp | 1.0M | $36.6M | -37.6K (-3.5%) | Trimmed |
| 12 | PRINCIPAL FINANCIAL GROUP INC | 958.0K | $33.9M | +10.4K (+1.1%) | Added |
| 13 | Pictet Asset Management Holding SA | 942.2K | $30.2M | -535.0K (-36.2%) | Trimmed |
| 14 | Public Sector Pension Investment Board | 677.4K | $24.0M | +6.2K (+0.9%) | Added |
| 15 | BNP PARIBAS FINANCIAL MARKETS | 528.0K | $18.7M | +97.6K (+22.7%) | Added |
| 16 | Invesco Ltd. | 524.3K | $18.5M | -14.4K (-2.7%) | Trimmed |
| 17 | UBS Group AG | 495.0K | $17.5M | -2.0M (-80.5%) | Trimmed |
| 18 | RHUMBLINE ADVISERS | 449.5K | $15.9M | +10.3K (+2.4%) | Added |
| 19 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 403.2K | $14.3M | +8.3K (+2.1%) | Added |
| 20 | Fisher Asset Management, LLC | 390.5K | $13.8M | -14 (-0.0%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALKS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.